Use of a Dual-agent Local Analgesic (Bupivacaine-meloxicam) for Abdominal Incisions in Patients Undergoing Retropubic Mid-urethral Sling Surgery

• Status: Not yet recruiting
• Trial end date: 2024-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study will compare the use of a dual-agent local analgesic (bupivacaine-meloxicam) for abdominal incisions in patients undergoing retropubic mid-urethral sling surgery to see if narcotic usage and pain are impacted.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: TriHealth Inc.
• Treatments: Bupivacaine; Meloxicam

Criteria

Inclusion Criteria:

• undergoing retropubic mid-urethral sling surgery (with concomitant anterior repair or urethrocele repair)

• English as first language

Exclusion Criteria:

• patients undergoing concomitant posterior repair, vaginal vault suspension, or any other intra-peritoneal surgeries including hysterectomy

• NSAID use within 7 days of surgery

• steroid use within 10 days

• daily opioid use in the last 3 months

• long acting opioids within 3 days

• any opioids within 24h

• patients unable to consent for themselves

• patients allergic to meloxicam or bupivacaine

• pregnant or lactating patients